A Phase 1/2 interventional study of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone and rituximab and lenalidomide in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma, sponsored by Genmab. Active, not recruiting at 57 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Genmab · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse — 16 open to participants now, 23 under way, 3 of them phase 3. epcoritamab · Lymphoma, Large B-Cell, Diffuse.
Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, this one has the largest enrollment, is one of 2 that started in 2020, is one of 3 in phase 1/2, reaches primary completion later than 5 of the 22 other live ones, and was the 2nd registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →16 of the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse are open now, in 5 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18+
Hospital Universitario Dr. Jose E. Gonzalez · Sites in Mexico
Ages 18–65
University of Miami · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
By country, each count listing its studies:
epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 3
First in 2020; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 543 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 41 across the 24 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.
13 studies in Lymphoma, Large B-Cell, Diffuse by Genmab: none open now, 9 under way, 4 of them phase 3. Of 3 finished, 2 (67%) have results posted.
Among the 13 studies in Lymphoma, Large B-Cell, Diffuse by Genmab, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 1/2, and was the 3rd registered.
Genmab’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2020.
8 of the studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672705Timothy VoorheesEpcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | 2026-12-31 |
| NCT05451810GenmabA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | 2027-03 |
| NCT06536049Yazeed SawalhaEpcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | 2027-08-31 |
| NCT04542824GenmabTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | 2027-09 |
| NCT07451652Hospital Universitario Dr. Jose E. GonzalezLow Dose Epcoritamab Plus GemOx in R/R DLBCL | 2027-09 |
Add all 8 to your calendar (.ics) → With an account.
Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Genmab’s 13 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied.
Trial details include:
Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned.
Participants who receive standard treatments will have intravenous (IV) infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned.
A Phase 1b/2, open-label, multinational, interventional trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab in combination with other standard of care (SOC) agents in participants with B-NHL.
All participants in the trial will receive epcoritamab, as monotherapy or in combination. The following regimens will be investigated:
The trial consists of two parts: Part 1 ('Dose Escalation') and Part 2 ('Dose Expansion'). The primary objective of Part 1 is safety, and it includes Arm 1-5 and Arm 10. Part 2 includes all 10 arms (Arm 1-10) and the primary goal of all arms, except Arm 7, is preliminary efficacy. For Arm 7, the primary goal is safety. Participants in Arm 1-5 and Arm 10 can only participate in either Part 1 or Part 2. Dose Limiting Toxicities (DLTs) will be assessed in Part 1 and for a selected number of participants in Arm 8 during a 28-day period (safety run-in). The arms are conducted in parallel.
Key Inclusion Criteria
Arm 1:
Arm 2: R/R FL
Arm 3: Newly diagnosed, previously untreated FL grade 1-3A
Arm 4:
Arm 5:
Arm 6: Newly diagnosed, previously untreated FL grade 1-3A
Arm 7:
Arm 8:
Arm 9:
Arm 10:
Key Exclusion Criteria
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In participants with previously untreated DLBCL.
Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone · Biological: Epcoritamab
In participants with R/R FL.
Biological: Epcoritamab · Drug: Rituximab and Lenalidomide
In participants with previously untreated FL.
Drug: rituximab and bendamustine · Biological: Epcoritamab
In participants with R/R DLBCL eligible for ASCT.
Drug: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin · Biological: Epcoritamab
In participants with R/R DLBCL ineligible ASCT.
Drug: gemcitabine and oxaliplatin · Biological: Epcoritamab
In participants with previously untreated FL.
Drug: rituximab and lenalidomide · Biological: Epcoritamab
In participants with FL who achieved a CR or PR after receiving SOC treatment in 1L or 2L.
Biological: Epcoritamab
In participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline.
Drug: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone · Biological: Epcoritamab
In participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy.
Drug: Lenalidomide · Biological: Epcoritamab
In participants with R/R DLBCL eligible for ASCT.
Drug: rituximab, ifosfamide, carboplatin, and etoposide phosphate · Biological: Epcoritamab
6 cycles (21-day cycles)
Also known as: R-CHOP
Drug pages: Rituximab · Lenalidomide
rituximab 6 cycles and lenalidomide 12 cycles (28-day cycles)
Also known as: R2
Drug pages: Rituximab · Bendamustine
6 cycles (28-day cycles)
Also known as: BR
3 cycles (21-day cycles)
Also known as: R-DHAX/C
Drug pages: Gemcitabine · Oxaliplatin
4 cycles (28-day cycles)
Also known as: GemOx
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
6 cycles (21-day cycles)
Also known as: R mini-CHOP
12 cycles (28-day cycles)
3 cycles (21-day cycles)
Also known as: R-ICE
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Drug pages: Rituximab · Lenalidomide
Rituximab 375 milligrams per meter squared (mg/m\^2) will be administered intravenously QW in Cycle 1 and Q4W in Cycles 2-5. Lenalidomide 20 mg will be administered orally daily for 21 days for 12 cycles.
Also known as: R2
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Part 1: Number of Participants With Dose limiting Toxicities (DLTs)
DLT events are defined as clinically significant adverse events (AEs) or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications as assessed per Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0.
Time frame: During the first cycle (Cycle length= 28 days) in each cohort
Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign. (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)
Part 2 (Except Arm 7): Overall Response Rate (ORR)
ORR is defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on Lugano criteria.
Time frame: Up to 3 years
Part 1 and 2: Clearance (CL) of Epcoritamab
Time frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)
Part 1 and 2: Area Under the Concentration-Time Curve (AUC) of Epcoritamab
Time frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)
Part 1 and 2: Maximum (Peak) Plasma Concentration (Cmax) of Epcoritamab
Time frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)
Part 1 and 2: Time to Reach Cmax (Tmax) of Epcoritamab
Time frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)
Part 1 and 2: Terminal Elimination Half-Life (t 1/2) of Epcoritamab
Time frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)
Part 1 and 2: Number of Immune Cell Populations
Immune cell populations in peripheral blood and tumor biopsies will be assessed.
Time frame: Up to 2 years
Part 1 and 2: Percentage of Immune Cell Populations
Immune cell populations in peripheral blood and tumor biopsies will be assessed.
Time frame: Up to 2 years
Part 1 and 2: Change From Baseline in Cytokine Levels up to Cycle 3
Change in cytokine levels in peripheral blood samples will be assessed.
Time frame: Up to Cycle 3 (cycle length = 21 days for Arms 1, 4, 8 and 10; cycle length = 28 days for Arms 2, 3, 5, 6 and 9; cycle length = 28 days (Cycle 1) and 56 days (Cycles 2, 3) for Arm 7)
Part 1 and 2: Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (DNA) Level up to End of Treatment (up to 2 Years)
Change in circulating tumor DNA levels will be assessed.
Time frame: Up to 2 years
Part 1 and 2: Number of Participants With Anti-Drug Antibodies (ADAs) to Epcoritamab
Time frame: Up to 3 years
Part 1: ORR
ORR is defined as the percentage of participants achieving CR or PR based on Lugano criteria.
Time frame: Up to 3 years
Part 1 and 2: Duration of Response (DOR)
DOR: the time from the first documentation of objective tumor response (CR or PR) to the date of first PD or death, whichever occurs earlier, based on Lugano criteria.
Time frame: Up to 3 years
Part 1 and 2: Time to Response (TTR)
TTR is defined as the time from Day 1 of Cycle 1 to first documentation of objective tumor response (CR or PR).
Time frame: Up to 3 years
Part 1 and 2: Progression Free Survival (PFS)
PFS is defined as the time from Day 1 of Cycle 1 to first documented PD or death due to any cause, whichever occurs earlier, based on Lugano criteria.
Time frame: Up to 3 years
Part 1 and 2: Overall Survival (OS)
OS is defined as the time from the date of first dose, to the date of death due to any cause.
Time frame: Up to 3 years
Part 1 and 2: Time to Next Anti-lymphoma Therapy (TTNT)
TTNT is defined as the time from Day 1 of Cycle 1 to first documented administration of subsequent anti-lymphoma therapy.
Time frame: Up to 3 years
Part 1 and 2: Percentage of Participants With Minimal Residual Disease (MRD) Negativity
It is defined as the percentage of participants with at least 1 MRD negative result.
Time frame: Up to 3 years
Part 1 and 2: Duration of minimal residual disease (MRD) negativity
Time frame: Up to 3 years
Part 2 (Arm 7): Percentage of Participants Who Converted From MRD Positivity to MRD Negativity
Time frame: Up to 3 years
Part 2 (Except Arm 7): Percentage of Participants with Complete Response (CR) in Arms 1 to 10
Time frame: Up to 3 years
Part 2 (Arm 7): Percentage of Participants With CR
It is defined as the percentage of participants who remain in complete remission or converting to complete remission after first trial drug administration.
Time frame: Week 24, Week 48, and Week 96
Part 1 and 2: Time to Complete Response (TTCR)
TTCR is defined as the time from first trial drug administration to the date of first documented complete response post-treatment.
Time frame: Up to 3 years
Part 1 and 2: Duration of Complete Response (DoCR)
DoCR is defined as the time from the first documentation of CR to the date of PD or death, whichever occurs first based on Lugano criteria.
Time frame: Up to 3 years
Part 2: Number of Participants with AEs (Except Arm 7)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign. (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)
Plan to share: No
Started Nov 2020 (actual). Primary completion is estimated for Sep 2027, 82 months after the start.
Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's planned 82 months is close to that.
Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epcoritamab
Lymphoma, Large B-Cell, Diffuse →